These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 19222905)

  • 1. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.
    Strauch S; Jantratid E; Dressman JB
    J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.
    Breier AR; Paim CS; Steppe M; Schapoval EE
    J Pharm Pharm Sci; 2005 Aug; 8(2):289-98. PubMed ID: 16124939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
    Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
    J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate.
    Jantratid E; Strauch S; Becker C; Dressman JB; Amidon GL; Junginger HE; Kopp S; Midha KK; Shah VP; Stavchansky S; Barends DM
    J Pharm Sci; 2010 Apr; 99(4):1639-53. PubMed ID: 19798752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choice of rotation speed (rpm) for bio-relevant drug dissolution testing using a crescent-shaped spindle.
    Qureshi SA
    Eur J Pharm Sci; 2004 Nov; 23(3):271-5. PubMed ID: 15489128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules.
    Piscitelli DA; Bigora S; Propst C; Goskonda S; Schwartz P; Lesko LJ; Augsburger L; Young D
    Pharm Dev Technol; 1998 Nov; 3(4):443-52. PubMed ID: 9834946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study.
    Homsek I; Parojcić J; Dacević M; Petrović L; Jovanović D
    Arzneimittelforschung; 2010; 60(9):553-9. PubMed ID: 21117498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.
    Agrawal S; Panchagnula R
    Int J Pharm; 2004 Dec; 287(1-2):97-112. PubMed ID: 15541917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data.
    Rossi RC; Dias CL; Donato EM; Martins LA; Bergold AM; Fröehlich PE
    Int J Pharm; 2007 Jun; 338(1-2):119-24. PubMed ID: 17343999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine.
    Gajendran J; Krämer J; Shah VP; Langguth P; Polli J; Mehta M; Groot DW; Cristofoletti R; Abrahamsson B; Dressman JB
    J Pharm Sci; 2015 Oct; 104(10):3289-98. PubMed ID: 26149619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets.
    Garcia-Arieta A; Gordon J; Gwaza L; Mangas-Sanjuan V; Álvarez C; Torrado JJ
    Mol Pharm; 2015 Sep; 12(9):3194-201. PubMed ID: 26237401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a two-step tier-2 dissolution method for blinded overencapsulated erlotinib tablets using UV fiber optic detection.
    Lu X; Xiao B; Lo L; Bolgar MS; Lloyd DK
    J Pharm Biomed Anal; 2011 Aug; 56(1):23-9. PubMed ID: 21620602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
    Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
    AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of dissolution test for lopinavir, a poorly water-soluble drug, in soft gel capsules, based on in vivo data.
    Donato EM; Martins LA; Fröehlich PE; Bergold AM
    J Pharm Biomed Anal; 2008 Jul; 47(3):547-52. PubMed ID: 18403160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled release reservoir mini tablets approach for controlling the drug release of Galantamine Hydrobromide.
    Khatavkar UN; Shimpi SL; Kumar KJ; Deo KD
    Pharm Dev Technol; 2012; 17(4):437-42. PubMed ID: 22697431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES) in multi-pH media using United States Pharmacopeia apparatus II and III.
    Li J; Yang L; Ferguson SM; Hudson TJ; Watanabe S; Katsuma M; Fix JA
    AAPS PharmSciTech; 2002; 3(4):E33. PubMed ID: 12916927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bio-relevant dissolution testing of hard capsules prepared from different shell materials using the dynamic open flow through test apparatus.
    Garbacz G; Cadé D; Benameur H; Weitschies W
    Eur J Pharm Sci; 2014 Jun; 57():264-72. PubMed ID: 24021609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug.
    Colón-Useche S; González-Álvarez I; Mangas-Sanjuan V; González-Álvarez M; Pastoriza P; Molina-Martínez I; Bermejo M; García-Arieta A
    Mol Pharm; 2015 Sep; 12(9):3167-74. PubMed ID: 26287948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.